# Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

> **NCT05887908** · PHASE3 · COMPLETED · sponsor: **Meiji Seika Pharma Co., Ltd.** · enrollment: 614 (actual)

## Conditions studied

- Complicated Urinary Tract Infection
- Acute Pyelonephritis
- cUTI
- AP

## Interventions

- **DRUG:** co-administration of cefepime and nacubactam
- **DRUG:** co-administration of aztreonam and nacubactam
- **DRUG:** imipenem/cilastatin

## Key facts

- **NCT ID:** NCT05887908
- **Lead sponsor:** Meiji Seika Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-23
- **Primary completion:** 2024-11-22
- **Final completion:** 2024-11-26
- **Target enrollment:** 614 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05887908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05887908, "Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05887908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*